key: cord-0257719-m3evrpz5
authors: Zhang, Z.; Bae, Y. E.; Bradley, J. R.; Wu, L.; Wu, C.
title: SUMMIT: An integrative approach for better transcriptomic data imputation improves causal gene identification
date: 2021-12-11
journal: nan
DOI: 10.1101/2021.12.09.21267570
sha: 15117ef52c1de05f1aa376af7747a64434f99777
doc_id: 257719
cord_uid: m3evrpz5

Genes with moderate to low expression heritability may explain a large proportion of complex trait heritability, but these genes are insufficiently captured in transcriptome-wide association studies (TWAS) partly due to the relatively small available reference datasets for developing expression genetic prediction models to capture the moderate to low genetically regulated components of gene expression. Here, we introduce a new method, Summary-level Unified Method for Modeling Integrated Transcriptome (SUMMIT), to improve the expression prediction model accuracy and the power of TWAS by using a large expression quantitative trait loci (eQTL) summary-level dataset. We applied SUMMIT to the eQTL summary-level data provided by the eQTLGen consortium, which involve 31,684 blood samples from 37 cohorts. Through simulation studies and analyses of GWAS summary statistics for 24 complex traits, we show that SUMMIT substantially improves the accuracy of expression prediction in blood, successfully builds expression prediction models for genes with low expression heritability, and achieves higher statistical power than several benchmark methods. In the end, we conducted a case study of COVID-19 severity with SUMMIT and identified 11 likely causal genes associated with COVID-19 severity.

One potential approach to improve the power of TWAS is to directly combine individual-level reference panel data from several consortia or studies, increasing the sample size of expression reference panel. While straightforward, privacy concerns and subject consents can preclude access to individual-level reference panel data, making this approach often practically infeasible. On the other hand, one may use summary-level expression panels (often publicly available) with much larger sample sizes to build expression prediction models. However, to date, there is limited exploration regarding how one can build expression prediction models using a summary-level expression panel.

In this work, we introduce Summary-level Unified Method for Modeling Integrated Transcriptome (SUMMIT), a novel method that integrates summary-level expression reference panel data, derived from much larger sample sizes, with trait GWAS results to identify associated genes for the trait of interest. Specifically, we build gene expression prediction models in blood based on the eQTL summary-level data provided by the eQTLGen consortium [33] . To date, eQTLGen consortium conducted the largest meta-analysis involving 31, 684 blood samples from 37 cohorts [33] , and the corresponding eQTL summary-level data have been released to be publically available. Through extensive simulation studies and analyses of GWAS summary statistics from 25 complex traits, we show that SUMMIT substantially improves the accuracy of expression prediction in blood, successfully builds expression prediction models for genes with low expression heritability, and identifies way more risk genes than benchmark methods. In the end, we conduct a case study on COVID-19 severity and identify 11 likely causal genes. The real data results are deposited into a user-friendly and freely available web portal (https://chongwulab.shinyapps.io/SUMMIT-app/), enabling practitioners to easily search and download significant gene-trait associations. test associations between predicted gene expression levels and the trait of interest for each fitted expression prediction model with satisfactory performance (with R 2 ≥ 0.005). Finally, we apply the Cauchy combination test to aggregate results from the fitted prediction models, which effectively quantifies the overall gene-trait associations.

In the simulation studies, we first evaluated the accuracy of expression imputation models generated by SUMMIT and benchmark methods and the corresponding statistical power. Next, we studied the impact of sample size on prediction performance and verified that SUMMIT recovered the information of individual-level expression reference panel from summary-level data.

First, we observed that SUMMIT performed better than two widely-used competing methods, The current standard practice of TWAS is to only analyze genes with imputation R 2 ≥ 0.01 and does not take into account genes with lower prediction performance (i.e., genes with imputation R 2 between 0.005 and 0.01). However, such genes may have larger causal effect sizes on the trait of interest [41] . To evaluate the performance of different methods under highly small heritable situations, we simulated data with h 2 e = 0.005. Figure 2a shows that SUMMIT achieved satisfactory TWAS-fusion (0.067%; 255% improvement) and PrediXcan (0.014%; 1651% improvement). This is because SUMMIT leverages the summary-level eQTL data with a larger sample size.

Next, we studied the impact of the size of expression reference panel (Supplementary Figure   2 ). As expected, the imputation R 2 increased as the sample size increased. For example, for the setting with h 2 e = 0.05 and p causal = 0.2, when the sample size increased from 300 to 31, 684, the average imputation R 2 increased from 0 to 0.0401, highlighting the gains of using a larger expression reference panel. Importantly, the imputation models became more stable (i.e., the variance decreased) as the sample size increased. Also, we confirmed that the imputation results from SUMMIT (average imputation R 2 : 0.0401) were highly similar to that of individual-level data available (average imputation R 2 : 0.0392), validating that SUMMIT can recover the individual-level information from summary-level data.

To consider the potential impact of genetic architecture, we considered two additional randomly selected genes, and the results were similar ( Supplementary Figures 3-6 ). Furthermore, we ran simulations 5,000,000 times (5,000 runs for each of 1,000 computed weights) under the null hypothesis to evaluate the Type 1 error rates, confirming that all methods maintained well-controlled Type 1 error rates (Supplementary Figure 7) .

In summary, these results demonstrated the potential usefulness of the SUMMIT for building expression prediction models and conducting subsequent association studies, especially for genes with low heritable expression.

We compared the accuracy of expression imputation models of SUMMIT and four benchmark methods, including MR-JTI, TWAS-fusion, PrediXcan, and UTMOST for whole blood tissue. We trained the SUMMIT models with eQTLGen summary data, and the four benchmark methods were trained with GTEx data. For a fair comparison, we compared the number of genes with an estimated R 2 ≥ 0.01 and only focused on the genes that appear in the eQTLGen summary data. The R 2

for the benchmark methods were based on cross validation and provided by the corresponding authors, and the R 2 for the SUMMIT was calculated based on the additional subjects in GTEx version 8 data, who have not been meta-analyzed in the eQTLGen and thus can be viewed as an 6 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101/2021.12.09.21267570 doi: medRxiv preprint independent external dataset. Compared with the benchmark methods, MR-JTI (9, 576 genes), TWAS-fusion (5, 411 genes), PrediXcan (7, 512 genes), and UTMOST (7, 236 genes), SUMMIT developed satisfactory prediction models for more genes (9, 749 genes with R 2 ≥ 0.01). Importantly, SUMMIT could build prediction models for the majority (8, 364 out of 11, 450; 73%) of genes that can be analyzed by either of benchmark methods, (Figure 3(a) ). In addition, SUMMIT was able to establish prediction models of additional 1, 836 genes that were ignored by benchmark methods, showing consistent improvement by using a large training dataset. Furthermore, compared with MR-JTI, SUMMIT achieved significantly higher prediction accuracy in different quantiles (p < 2.2 × 10 −16 by the Kolmogorov-Smirnov test). This was also true for other methods (PrediXcan: p < 2.2 × 10 −16 ; TWAS-fusion: p < 2.2 × 10 −16 ; and UTMOST: p < 2.2 × 10 −16 ).

To evaluate the performance of identifying significant associations, we applied SUMMIT to the summary statistics of 24 GWAS (N total ≈ 5, 600, 000 without adjusting for sample overlap across studies, Supplementary Table 1 ) and compared the results with those of the benchmark methods (for all genes with R 2 ≥ 0.01). The full association results for SUMMIT were summarized in Supplementary Table 1 . While the SUMMIT analyzed all genes with R 2 ≥ 0.005 and applied the Bonferroni correction accordingly, we focused on the genes with R 2 ≥ 0.01 for a fair comparison Because different methods test different sets of genes, we also compared methods over a common set of 4, 291 genes that could be analyzed by all the methods (Figure 3 (c)). Again, SUMMIT maintained an edge over competing methods, showing 35% improvement (p = 0.00053 by the paired Wilcoxon rank test) compared with the second best performing method, UTMOST.

Importantly, SUMMIT was applicable to analyze genes with low heritability for the expressions (0.005 ≤ R 2 < 0.01), which have been largely ignored by benchmark methods. Out of the 11, 585 7 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101/2021.12.09.21267570 doi: medRxiv preprint genes with R 2 ≥ 0.005, 1, 836 had testing R 2 between 0.005 and 0.01. For these 1, 836 genes, we identified 607 gene-trait associations (Figure 3(b) ). In comparison, for the remaining 9, 749 genes, we identified 3, 759 gene-trait associations, indicating that genes with relatively smaller R 2 may be equally important as those with larger R 2 . This finding is aligned with the fact that genes with low expression heritability have substantially larger causal effect sizes on complex traits [41] .

2.5 SUMMIT achieves higher predictive power for identifying "silver standard"

genes We compared different methods in terms of identifying the likely causal genes that mediate the association between GWAS loci and the traits of interest. Following [2] , we used a set of 1,258 likely causal gene-trait pairs curated by using the OMIM (Online Mendelian Inheritance in Man) database [13] and a set of 29 gene-trait pairs based on rare variant results from exome-wide association studies [18, 22, 24] , which provide orthogonal information that is independent of GWAS results. Both gene-trait pairs sets can be found in Supplementary Table 2.

Figure 3(d) shows that SUMMIT yielded good sensitivity and specificity for identifying the silver standard genes and achieved the highest AUC (0.731) among all the methods compared. All methods achieved relatively good sensitivity and specificity, showcasing the potential predictive ability of TWAS-type methods to prioritize putative causal genes. For example, with Bonferroni correction cutoffs, SUMMIT identified 80 (54%) genes in the silver standard gene list, whereas the second best performing method, PrediXcan, identified 57 (39%). In summary, perhaps due to the improvement in expression prediction models, SUMMIT achieved higher predictive power in terms of prioritizing likely causal genes. Table 3 ). For these 17 genes identified by SUMMIT, 11 was prioritized by a fine-mapping method FOGS (Table 1) . We further validated these 11 genes by analyzing COVID-19 comparing very severe respiratory confirmed COVID-19 versus population controls (A2). Of them, 10 were validated at P < 0.05. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101/2021.12.09.21267570 doi: medRxiv preprint viral load [17, 26] and CD4+ T cell counts. Such chemokine receptor-ligand interactions mediating the traffic of inflammatory cells and pathogen-associated immune responses could be plausible for being related to COVID-19 severity. For FLT1P1, its expression was reported to be positively associated with predicted neutrophil count [45] . This may mediate the genetic link between this gene and COVID-19 severity. Another identified genes, CCR5, is known to play a role in immune cell migration and inflammation. A study found that CCR5 blockade in critical COVID-19 patients induced decreased inflammatory cytokines, increased CD8 T-cells, and decreased SARS-CoV2 RNA in plasma [29] . For OAS1, both predicted and measured protein levels are inversely associated with COVID-19 susceptibility and severity, which is consistent with the current study's finding [46] .

Two of the other genes, namely, OAS3 and IFNAR2, have been identified in our earlier work of COVID-19 TWAS using complementary methods and designs [38] .

By leveraging the summary-level expression reference panel with a much larger sample size, our new method SUMMIT substantially improved the prediction accuracy of built expression prediction models, which in turn increased the power for identifying risk genes for complex traits. The corresponding software SUMMIT and its tutorial are available at GitHub.

Through simulations and analyses of GWAS results for 25 traits, we demonstrated the substantial performance gain of SUMMIT over existing methods. Briefly, we demonstrated that SUM-MIT improved the expression imputation accuracy (built more expression prediction models with R 2 ≥ 0.01), identified more associations, and achieved higher predictive power for identified 'silver standard' genes. Importantly, SUMMIT was applicable to analyze genes with low expression heritability (with R 2 between 0.005 and 0.001), which have larger causal effects sizes on complex traits [41] but have been largely ignored by existing methods.

SUMMIT can be viewed as one type of gene-based Mendelian randomization and provide valid causal interpretations when all genetic variants used in expression prediction models (with nonzero weights) are valid instrumental variables [5, 40, 42] . However, with the wide-spread horizontal pleiotropy of genetic variables [19] , valid instrumental variables assumptions may be violated and 11 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101/2021.12.09.21267570 doi: medRxiv preprint thus we recommend practitioners using multiple complementary methods jointly to identify likely causal genes. For example, we can apply fine-mapping approaches such FOCUS [23] and FOGS [37] to further prioritize likely causal genes by modeling the linkage disequilibrium and correlation among TWAS signals.

There are several limitations in our current study. First, the summary data of eQTLGen are for whole blood in European ancestry; thus, the built gene expression prediction models would be applicable only for blood tissue of European ancestry subjects. While SUMMIT can be equally applied to other tissues and ancestry, the corresponding summary eQTL data would be needed for such extensions. Second, several TWAS methods such as UTMOST [14] and MR-JTI [44] have been proposed to leverage expression from other tissues or functional annotations to improve the prediction accuracy of expression prediction models. We expect that the number of analyzable genes can be further increased when we integrate this informative information. Third, similar to most existing TWAS methods, the results of SUMMIT imply causality only when valid instrumental variable assumptions are met. A partial solution is to apply fine-mapping to prioritize likely causal genes. However, the robustness of SUMMIT would be significantly improved if we can relax these stringent valid instrumental variable assumptions. We leave this exciting topic to future research.

In conclusion, SUMMIT is a novel and powerful framework to perform TWAS. It integrates summary-level eQTL data with GWAS summary statistics via advanced statistical methods. When combined with fine-mapping and functional validations, its findings may gain insights into the genetic basis of diseases and benefit the development of new therapies. To facilitate such efforts, we deposit TWAS results of 26 traits described in the manuscript into a user-friendly server (https: //chongwulab.shinyapps.io/SUMMIT-app/) such that practitioners can search and download gene-trait association results.

12 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Consider the following linear regression model for estimating the genetically regulated expression:

where Y is the N -dimensional vector of gene expression levels of a gene of interest (corrected for important covariates like age, gender, and genotype principal components), X = (X 1 , · · · , X p ) is the N × p standardized genotype matrix of p cis-SNPs around the gene (within 1 MB of the gene transcription start site and transcription end site), the p-dimensional vector w = (w 1 , · · · , w p ) is the cis-eQTL effect size, and is random noise with mean zero.

We estimate w using a penalized regression framework. Specifically, the objective function is

where J λ (·) is a penalty term. Since the performance of different penalties may vary under different genetic architecture, we consider several penalties, including LASSO [32] , elastic net [48] , minimax concave penalty (MCP) [43] , smoothly clipped absolute deviation (SCAD) [7] , and MNet [15] .

Note that the objective function (Equation (2)) is a function of the marginal statistics X Y /N and the linkage disequilirium (LD) matrix X X/N , and does not require observing and storing the individual-level data. This allows us to build expression prediction models using eQTL summarylevel data, which are computed using a much larger sample size. That is, rewrite the objective function as

where r = X Y /N = (r 1 , · · · , r p ) is a p-dimensional vector of standardized marginal effect size for cis-SNPs (i.e., correlation between cis-SNPs and gene expression levels), and R = X X/N is 13 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101/2021.12.09.21267570 doi: medRxiv preprint the LD matrix of cis-SNPs. We use the z-scores provided in the summary-level eQTL dataset to estimate r (denoted byr) and use a shrinkage estimator (shall be illustrated later) with a LD reference panel (such as 1000 Genomes Project [1]) to estimate R (denoted byR). We add an L 2 penalty term θw w (where θ ≥ 0) to the objective function, which ensures a unique solution upon optimization. Notice that Y Y /N does not depend on w and can be ignored when optimizing f . Thus, the final objective function that we optimize can be written as,

The estimatesŵ can be obtained by the coordinate descent algorithm [9] , which solves the univariate penalized regression problem sequentially and iteratively. Briefly, suppose that (ŵ

are the coefficients at the t-th iteration of the coordinate descent algorithm. Define z The convergence properties of the coordinate descent algorithm guarantee a local minimum for w [9] . We put details on optimization, including choices for initial starting values, λ, and θ and updating formulas for other penalties to the Supplementary Note.

The standardized marginal effect size r j is often not provided in eQTL summary-level data, but it can be well approximated byr j = Z j / N j − 1 + Z 2 j , where Z j and N j are the z-score and sample size for cis-SNP j, respectively. The eQTL summary-level data combine the results from multiple cohorts and thus the sample size for each SNP may vary. To yield unbiased estimation, we use the SNP-specific sample size N j instead of the largest sample size (cohort size) [28] .

The objective function (4) involves a estimated LD correlation matrixR. Instead of using 14 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. data, we use the shrinkage estimator of the LD matrix [21, 35, 47] , which stabilizes the results by shrinking the off-diagonal entries towards zero. Specifically, we first calculate the sample LD correlation matrix from a reference panel. Each entry of the LD correlation matrix is then multiplied by the factor exp(− 2Nec ij m ), where N e is the effective population size, m is the sample size of the data for generating the genetic map, and c i j is the genetic distance between sites i and j in centiMorgans scale. The entries are set to zero if the factor exp(− 2Nec ij m ) is less than a pre-specified threshold c. Following others [21, 47] , we use the genetic distance generated from the 1000 Genomes OMNI arrays with N e = 11, 400 and m = 183 and the pre-specified threhold c was set to 1 × 10 −3 .

We trained our expression prediction model by using the cis-eQTLs summary-level data from eQTLGen [33] , which consist of the effect sizes of more than 11 million SNPs from 31, 684 blood samples. Following PrediXcan [10] , SNPs in the vicinity of the given gene (within 1 Mbp of the gene transcription start site and transcription end site) were used as the cis-genotype information.

Further, we filtered out all SNPs with a minor allele frequency < 0.01 and those were non-biallelic or ambiguous or not in HapMap 3 SNPs set [10] .

We used both genotype and gene expression data in the GTEx project (version V7, dbGaP Accession number phs000424.v7.p2) [31] to select the tuning parameters. The processed gene expression in whole blood (N = 369) were downloaded from the GTEx website. Briefly, the RPKMs in each sample was standardized and normalized by quantile-transformation. Expression for each gene was further adjusted by performing a multivariate linear regression with sex, genotyping platform, 35 PEER factors and three genotype-based principal components (PCs) and the residuals were used as processed expression levels. We used the squared correlation between the predicted and observed expression (that is, R 2 ) to select the best tuning parameters. Of note, the subjects in GTEx v6 (N = 336; 1.1%) have been meta-analyzed in eQTLGen [33] and may result in sub-optimal tuning parameters.

We used independent subjects that are in GTEx v8 but not in GTEx v7 (N = 309) as external validation data. Of note, these subjects in GTEx v8 have not been meta-analyzed in eQTLGen 15 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101/2021.12.09.21267570 doi: medRxiv preprint and thus can be viewed as an external validation. Because genes with low expression heritability have substantially larger causal effect sizes on complex traits [41] , we selected the models with R 2 ≥ 0.005 instead of the commonly used criterion of R 2 ≥ 0.01.

When individual-level GWAS data (genotype data X new , phenotype P new , and covariance matrix C new ) are available, one can apply a generalized linear regression model

is a link function, and X newŵ is the predicted genetically regulated expression.

When only summary-level GWAS data are available, one can apply a burden type test:

where Z is the vector of z-scores for all cis-SNPs and V is the linkage disequilibrium (LD) matrix of analyzed SNPs (which can be estimated by a population reference panel such as 1000 Genomes

Project [1]).

To further improve the power, we apply the Cauchy combination test [20] to integrate information from K models that have R 2 ≥ 0.005. Specifically, we use the following test statistics:

where p j is the P -value for model j andR 2 j is calculated by R 2 j / k j=1 R 2 j . T follows a standard

Cauchy distribution approximately, and the P -value can be calculated as 0.5 − arctan(T )/π. Of note, we useR 2 j as weights when combining multiple expression prediction models because a larger R 2 j indicates a better expression prediction model. The Cauchy combination test has been widely 16 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101/2021.12.09.21267570 doi: medRxiv preprint used in the human genetics community [20, 36] , because the P -value approximation is accurate for the highly significant results (which are of interest) and there is no need to estimate the correlation structure among the combined P -values.

One may be interested in the association direction for a specific gene. For the majority of significant genes identified by SUMMIT, all the expression prediction models yield the same association direction. When expression prediction models provide conflicting association direction, we determine the association direction by the majority voting. In the rare situation where the number of models indicating positive associations equals the number of models indicating negative associations, we declare the association direction is unknown.

We conducted extensive simulation studies to evaluate how the size of the expression reference panel impacts the expression prediction accuracy and the subsequent power of TWAS. Also, we evaluated whether using the summary-level eQTL data achieves similar performance to that of using individual-level expression reference panel. Specifically, we used data from the UK Biobank (application number 48240) and randomly chose genotype data from 31, 684 (to match the sample size of the eQTLGen data) independent White British individuals as training data, genotype data from additional 369 (to match the sample size of GTEx v7 data) independent White British individuals as tuning data, and genotype data from additional 10, 000 independent White British individuals as test data. The imputed genetic 877 cis-SNPs (with minor allele frequency (MAF) > 1%, Hardy-Weinberg p-value > 10 −6 , and imputation "info" score > 0.4) of the arbitrarily chosen gene CHURC1 were used for our main simulations. We also considered several other randomly selected genes.

We simulated gene expression levels and phenotype values by E g = Xw + e and Y = βE g + p , respectively. X is standardized genotype matrix, w is the effect size, e ∼ N (0, 1 − h 2 e ), and p ∼ N (0, 1 − h 2 p ), where h 2 e and h 2 p were the expression heritability (i.e., the proportion of gene effect sizes for the remaining non-causal SNPs were set to 0. We re-scaled the effect sizes w and β to achieve the targeted h 2 e and h 2 p .

To evaluate the performance of proposed method SUMMIT, we performed an association scan on the whole simulated training data (E g , X) and computed the summary-level data (i.e., Z scores) by a linear regression. Besides building models with summary-level data, we also built prediction models with individual-level data of different sample sizes (300, 600, 3, 000, 10, 000, 31, 684). We compared SUMMIT with two widely used methods, PrediXcan [10] and TWAS-fusion [11] . We trained models with PrediXcan and TWAS-fusion with individual-level data of 670 samples (to match the sample size of blood tissue in GTEx v8 data).

We considered comprehensive scenarios that varied the proportion of causal 

To demonstrate the potential usefulness of the SUMMIT, we further compared SUMMIT with several TWAS methods, including MR-JTI [44] , PrediXcan [10] , TWAS-fusion [11] , and UTMOST [14] for whole blood tissue in the following aspects.

First, we compared prediction accuracy (in terms of R 2 ) estimated by different methods. Of note, while the prediction performance of competing methods was estimated through cross validations, the prediction performance of SUMMIT was estimated in an external testing dataset. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101/2021.12.09.21267570 doi: medRxiv preprint numbers of analyzable genes. To make a fair comparison, we also evaluated the common gene set that can be analyzed by all methods and used the same Bonferroni correction cutoff to determine the significant gene sets. The number of significant genes identified by different methods was further compared by Wilcoxon signed-rank test, which compares two matched samples to test whether their population mean ranks differ.

Third, as TWAS can be viewed as a special case of Mendelian randomization [34] , we further compared different methods in terms of identifying the causal genes that mediate the association between GWAS loci and the traits of interest. Following [2] , we curated a set of likely causal genetrait pairs using information that is independent of GWAS results. Briefly, we utilized the OMIM (Online Mendelian Inheritance in Man) database [13] and rare variant results from exome-wide association studies [18, 22, 24] , leading to 1, 287 gene-trait pairs. We used LDetect to partition the genome into approximately independent LD blocks [3] and refined the gene-trait pairs by only considering the genes that were located in LD blocks with at least one genome-wide significant variant, leading to 148 likely causal gene-trait pairs (among 24 distinct traits). We denote the curated set as "silver standard" to highlight their imperfect nature. We compared different methods by the area under receiver operating characteristic curve (AUC).

To identify novel genes associated with COVID-19 severity, we applied SUMMIT to the GWAS summary data from The COVID-19 HGI (Release 5 (January 2021)) [16] . The detailed information for participating studies, quality control, and analyses have been included on the COVID-19 HGI website (https://www.covid19hg.org/results/). Briefly, data from 9, 986 hospitalized COVID-severity. In the end, we evaluated associations of identified genes with additional COVID-19 phenotype. Briefly, we leveraged A2 ALL eur (Europeans; 5, 101 cases and 1, 383, 241 controls) for comparing very severe respiratory confirmed COVID vs population controls.

The GWAS summary data (with download link) used in this study are summarized in Supplementary 

The software SUMMIT and the code for reproducing the results described in this study will be available from GitHub (https://github.com/ChongWuLab/SUMMIT).

This study is supported by National Institutes of Health (R03 AG070669) and has been conducted using the UK Biobank recourse (application numbers 48240). The authors would like to thank all of the individuals for their participation in GWAS studies and UK Biobank and all the researchers, clinicians, technicians and administrative staff for their contribution to the studies and making their GWAS summary results publicly available. 20 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101/2021.12.09.21267570 doi: medRxiv preprint

A global reference for human genetic variation

Exploiting the gtex resources to decipher the mechanisms at gwas loci

Approximately independent linkage disequilibrium blocks in human populations

An expanded view of complex traits: from polygenic to omnigenic

Use of allele scores as instrumental variables for mendelian randomization

The gtex consortium atlas of genetic regulatory effects across human tissues

Variable selection via nonconcave penalized likelihood and its oracle properties

Partitioning heritability by functional annotation using genome-wide association summary statistics

Regularization paths for generalized linear models via coordinate descent

A gene-based association method for mapping traits using reference transcriptome data

Integrative approaches for large-scale transcriptome-wide association studies

Transcriptome-wide association study of schizophrenia and chromatin activity yields mechanistic disease insights

Online mendelian inheritance in man (omim), a knowledgebase of human genes and genetic disorders

A statistical framework for cross-tissue transcriptome-wide association analysis

The mnet method for variable selection

Mapping the human genetic architecture of covid-19 by worldwide meta-analysis

Ccr5as lncrna variation differentially regulates ccr5, influencing hiv disease outcome

Exome-wide association study of plasma lipids in¿ 300,000 individuals

Trans effects on gene expression can drive omnigenic inheritance

ACAT: A fast and powerful p value combination method for rare-variant analysis in sequencing studies

Improved polygenic prediction by bayesian multiple regression on summary statistics

Exome sequencing of finnish isolates enhances rare-variant association power

Probabilistic fine-mapping of transcriptome-wide association studies

Rare and low-frequency coding variants alter human adult height

Systematic localization of common disease-associated variation in regulatory dna

Polymorphisms of large effect explain the majority of the host genetic contribution to variation of hiv-1 virus load

Tigar: An improved bayesian tool for transcriptomic data imputation enhances gene mapping of complex traits

Statistical correction of the winner's curse explains replication variability in quantitative trait genome-wide association studies

Ccr5 inhibition in critical covid-19 patients decreases inflammatory cytokines, increases cd8 t-cells, and decreases sars-cov2 rna in plasma by day 14

Integrative transcriptome analyses of the aging brain implicate altered splicing in alzheimer's disease susceptibility

Genetic effects on gene expression across human tissues

Regression shrinkage and selection via the lasso

Unraveling the polygenic architecture of complex traits using blood eqtl meta-analysis. bioRxiv

Opportunities and challenges for transcriptome-wide association studies

Using linear predictors to impute allele frequencies from summary or pooled genotype data

A gene-level methylome-wide association analysis identifies novel alzheimer's disease genes

A powerful fine-mapping method for transcriptome-wide association studies

An integrative multiomics analysis identifies putative causal genes for covid-19 severity

A powerful framework for integrating eQTL and GWAS summary data

Some statistical consideration in transcriptome-wide association studies

Quantifying genetic effects on disease mediated by assayed gene expression levels

Testing and controlling for horizontal pleiotropy with probabilistic mendelian randomization in transcriptome-wide association studies

Nearly unbiased variable selection under minimax concave penalty

A unified framework for joint-tissue transcriptome-wide association and mendelian randomization analysis

Altered blood cell traits underlie a major genetic locus of severe covid-19

A neanderthal oas1 isoform protects individuals of european ancestry against covid-19 susceptibility and severity

Bayesian large-scale multiple regression with summary statistics from genome-wide association studies

Regularization and variable selection via the elastic net

All rights reserved. No reuse allowed without permission.